Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 14, 2025 | – | -$0.28 | |
| Aug 14, 2025 | -$0.96 | -$0.31 | Beat |
| May 14, 2025 | -$1.28 | -$0.64 | Beat |
| Mar 27, 2025 | -$2.43 | -$1.19 | Beat |
| Nov 14, 2024 | -$0.96 | -$1.29 | Miss |
| Aug 13, 2024 | -$0.96 | -$0.96 | Beat |